Digestery
Everyday supplements › Fish Oil and the Heart › Studies

Trial, not randomized · measured the question itself

Trial analysis in 7,026 adults: icosapent ethyl cut heart events regardless of lipoprotein(a) level

Szarek and colleagues · Journal of the American College of Cardiology · 2024

Original title: Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Heart event reductions with icosapent ethyl did not vary across lipoprotein(a) levels (interaction P > 0.10). Icosapent ethyl cut first major heart events in groups with levels at or above 50 mg/dL and below 50 mg/dL.

The study at a glance

Type of study
Trial, not randomized
Who or what was studied
7,026 people · adults on statins with high triglycerides and heart disease, or diabetes with other risk factors, with a lipoprotein(a) blood test
What was tested
Icosapent ethyl 2 g twice a day versus placebo, looking at results by lipoprotein(a) blood level
What it measured
The question itself: heart attacks, strokes and heart deaths
Daily amount
4 g a day
Who has a stake
Company stake
Supported by Amarin, which sells icosapent ethyl; three authors are Amarin employees and stockholders.
Journal
Journal of the American College of Cardiology, 2024
Source
PubMed record 38530686. This page is based on the abstract only.

How much this study counts

  • –Not randomized: the groups may differ in ways that affect the result.
  • ✓Compared with a placebo, a dummy treatment.
  • ✓Large: 7,026 people.
  • ✓Measured the question itself: heart attacks, strokes and heart deaths.
  • –Company stake: Supported by Amarin, which sells icosapent ethyl; three authors are Amarin employees and stockholders.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: heart attacks, strokes and heart deaths

    11

    7 benefit, 4 no difference

    ↑ This study is the ringed dot

  2. Trials in people: other measures

    3

    1 benefit, 2 no difference

  3. Trials in people: lab tests or safety

    0

    None among the papers we read.

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does fish oil prevent heart disease?”

Little or no effect in most trials.

Confidence: moderate. Based on 21 on-topic papers.

Read the full answer

Of the other 10 papers on the same step: 6 benefit, 4 no difference. This one found benefit. It agrees with most of them.

Other papers on the same step

See all 21 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.